glutaminase has been researched along with Adenocarcinoma--Clear-Cell* in 1 studies
1 other study(ies) available for glutaminase and Adenocarcinoma--Clear-Cell
| Article | Year |
|---|---|
GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumors.
Targeting glutamine metabolism has emerged as a novel therapeutic strategy for several human cancers, including ovarian cancer. The primary target of this approach is the kidney isoform of glutaminase, glutaminase 1 (GLS1), a key enzyme in glutamine metabolism that is overexpressed in several human cancers. A first-in-class inhibitor of GLS1, called CB839 (Telaglenastat), has been investigated in several clinical trials, with promising results. The first clinical trial of CB839 in platinum-resistant ovarian cancer patients is forthcoming. Topics: Adenocarcinoma, Clear Cell; Animals; DNA-Binding Proteins; Female; Glutaminase; Glutamine; Humans; Mice; Ovarian Neoplasms; Protective Factors; Transcription Factors | 2022 |